João Paulo-Fernandes

Mr. João Paulo-Fernandes

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
TPTiago Afonso Pina-Cabral
Tiago Afonso Pina-Cabral
JPJosé Pereira
José Pereira
JPJoão Paulo-Fernandes
João Paulo-Fernandes
MSMárcia Silva
Márcia Silva
MFMário Fontes-Sousa
Mário Fontes-Sousa
PCPatrícia Cavaco
Patrícia Cavaco
Background: Real-world safety profiles of immune checkpoint inhibitors (ICIs) in older adults remain insufficiently characterized. Although ICIs are widely used across tumor types, older patients, particularly those with frailty, multimorbidity, or polypharmacy, are consistently under-represented in clinical trials, limiting the external validity of trial-derived toxicity estimates. Robust real-world data are therefore essential to clarify the incidence, seriousness, and age-related patterns of immune-related adverse events (irAEs) in routine practice. Methods: This is a nationwide retrospective study of spontaneous ICI-related ADRs reported in INFARMED’s Portal RAM (2011–2024). We evaluated the frequency, seriousness, fatality, and organ-specific patterns of ICI-related adverse drug reactions (ADRs) reported to the Portuguese National Pharmacovigilance System. The analytic unit was the ADR case. Endpoints included seriousness (primary), fatality, hospitalization, time-to-onset, and System Organ Class. Multivariable logistic regression adjusted for age, sex, regimen, tumor type, polypharmacy, and calendar period; sensitivity analyses using first ADR per patient were concordant. Results: We identified 2300 eligible ICI-related ADRs (corresponding to 925 patients). Median age at the time of ADR was 65 years (IQR not reported); 33.7% occurred in adults aged ≥70 years, and 62.8% of reports involved male patients. PD-1 inhibitors accounted for 77.5% of ADRs, and monotherapy for 72.9%. Overall, 85.8% of ADRs were classified as serious; 17.9% led to hospitalization and 19.1% were fatal. Serious-event reporting was similar in older and younger adults (≥70 vs. <70 years: 84.5% vs. 86.5%, p = 0.22), and the proportion explicitly labeled immune-related did not differ (9.3% vs. 8.7%, p = 0.56). In contrast, fatal outcomes were significantly more common in older adults (25.3% vs. 16.0%; p < 0.001). Age was associated with distinct organ-specific patterns. Adults ≥ 70 years had higher odds of nervous system disorders (aOR 1.75, 95% CI 1.23–2.48) and immune system disorders (aOR 1.42, 95% CI 1.02–1.98), but lower odds of hepatobiliary (aOR 0.52, 95% CI 0.36–0.76; p = 0.001) and blood/lymphatic disorders (aOR 0.50, 95% CI 0.32–0.79). In multivariable models, age ≥ 70 years did not predict seriousness (aOR 0.98, 95% CI 0.76–1.27), whereas combination therapy remained independently associated with increased seriousness (aOR 1.57, 95% CI 1.13–2.18). Conversely, age ≥ 70 years independently predicted fatal outcomes (aOR 1.66, 95% CI 1.31–2.09). Later calendar periods (2017–2024) were associated with substantially lower fatality (aOR 0.16; 95% CI 0.10–0.27). CTLA-4-containing regimens demonstrated a tendency toward higher fatality (aOR 1.50; 95% CI 0.94–2.37). Conclusions: Chronological age does not seem to increase the likelihood of reporting a serious ICI-related ADR, but, once toxicity occurs, older adults experience higher fatality rates. Age-related phenotypic differences and regimen-specific risks highlight the need for early recognition systems and tailored toxicity management in older populations.

26 February 2025 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
JMJorge Monteiro
Jorge Monteiro
DADiogo Almeida
Diogo Almeida
JPJoão Paulo-Fernandes
João Paulo-Fernandes
BSBruno Sepodes
Bruno Sepodes
CTCarla Torre
Carla Torre
Risk management in oncology is critical due to toxicity, narrow therapeutic windows, and strict dosing schedules. This study analyzed post-authorization studies from the HMA-EMA Real-World Data Catalogues evaluating the effectiveness of risk minimization measures (RMM) for oncology medicines. We reviewed all RMM effectiveness studies registered in the HMA-EMA RWD Catalogues until February 2024, focusing on medicines classified under ATC codes 'L' and 'V10' for oncological conditions. Data from protocols and reports were analyzed, including study design, population, objectives, RMM types, process and outcomes indicators and reported effectiveness. Out of 1,280 records, 21 studies met the inclusion criteria. Most studies (81%) were cross-sectional surveys, 57% targeted healthcare professionals, and 86% used primary data. Additional RMMs were evaluated in 81% of studies. Process indicators were assessed in nearly all studies, but only 5% included outcome indicators. Of the 15 studies with available results, 60% were deemed effective, 27% inconclusive, and 13% ineffective by the sponsors. Future studies should set success thresholds in advance, use a dual evidence approach to measure outcomes, and consider new methods to increase participant numbers. Feasibility assessments prior to conducting studies are essential for achieving meaningful objectives in oncology risk management.

17 June 2026 in International Journal of Gastronomy and Food Science
Verified
Journal Article
Open access
JPJoão Paulo-Fernandes
João Paulo-Fernandes
ÓCÓ. Cabral
Ó. Cabral

29 September 2026 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
MLMarta Raquel Costa Loureiro
Marta Raquel Costa Loureiro
JPJoão Paulo-Fernandes
João Paulo-Fernandes
APAntónio Paranhos
António Paranhos
Introduction: Schizophrenia is a chronic and heterogeneous psychiatric disorder characterized by positive and negative symptoms, together with cognitive dysfunction. Because current antipsychotic-based treatment remains limited for negative and cognitive symptoms, adjunctive strategies targeting additional pathophysiological pathways are needed. Methods: This narrative review synthesized preclinical and clinical evidence on selected medicinal plants, standardized extracts and plant-derived bioactive compounds investigated as adjunctive approaches in schizophrenia. Evidence was organized according to plant source or compound, putative mechanisms of action, preclinical findings, clinical evidence, symptom domains, antipsychoticassociated adverse effects and pharmacological pathways. Results: The reviewed interventions targeted oxidative stress, neuroinflammation, glutamatergic and dopaminergic dysfunction, endocannabinoid modulation, mitochondrial function and neurotrophic signaling. Randomized clinical evidence was available for a limited subset of candidates, including cannabidiol, Withania somnifera, L-theanine, curcumin-based formulations, Ginkgo biloba and Panax quinquefolius. Most other agents remained supported mainly by preclinical, mechanistic or indirect clinical evidence. Potential benefits included improvement in positive, negative or cognitive symptom domains and attenuation of selected antipsychotic-associated adverse effects. Discussion: The evidence base remains heterogeneous, with substantial variation in formulations, doses, treatment duration, outcome measures and translational maturity. Bioavailability and standardization are major challenges for several compounds, particularly polyphenols. Conclusion: Plant-based interventions should be positioned as adjunctive, not alternative, approaches. Further adequately powered clinical trials using standardized preparations are required to clarify efficacy, safety, optimal dosing and clinical relevance in schizophrenia.